Navigation Links
Quadra-Coil® Multi-Length Ureteral Stents

ProductsQuadra-Coil® Multi-Length Ureteral Stents
Company GYRUS ACMI
Item Quadra-Coil® Multi-Length Ureteral Stents
Features 
  • Accommodates ureteral lengths from 22 cm to 28 cm > Saves inventory, shelf space, and resources
  • Exclusive 360 kidney curl > Provides stability and reduces trauma during removal
  • Exclusive bladder curl design balances with the kidney curl > Helps reduce potential migration; expands to 28 cm length; reduces trigone irritation
  • Tecoflex® construction > Firm during placement for easier stent passage, then softens at body temperature for increased patient comfort
  • Hydrophilic coating inside and outside > Advance over any guidewire and through difficult anatomy.
Description High performance Tecoflex stents that save inventory, shelf space, and resources, Quadra-Coil Multi-Length Ureteral Stents accommodate ureteral lengths from 22 cm to 28 cm. An advanced hydrophilic coating allows the Quadra-Coil to glide over any guidewire and through the most difficult anatomy. These stents provide ease of placement and patient comfort in a multi-length stent. Each Quadra-Coil Multi-Length Ureteral Stent Kit contains one Quadra-Coil Multi-Length Ureteral Stent and one RAMROD™ Metal Tip Push Catheter.
Info GYRUS ACMI
Customer Service: (508) 804-2600
Web site: http://www.acmicorp.com

Related medicine products :

1. Endo-Sof™ Multi-Length Stent Sets
2. Multi-Length Stent Sets - C-Flex®
3. Multi-Length Stent Sets - Sof-Flex®
4. Open-ended Tapered Tip Ureteral Catheter (Left Ureter)
5. 20 Angled Tip Ureteral Catheter Set
6. Open-ended Tapered Tip Ureteral Catheter (Right Ureter)
7. 40 Angled Tip Ureteral Catheter Set
8. Cone-tip Ureteral Catheter
9. Whistle-tip Ureteral Catheters (Right Ureter)
10. Whistle-tip Ureteral Catheters (Left Ureter)
11. Dual Lumen Ureteral Access Catheter
Other Medicine News:Health News:Express Scripts Announces Definitive Agreement to Acquire WellPoint NextRx Subsidiaries for $4.675 Billion 2Health News:Express Scripts Announces Definitive Agreement to Acquire WellPoint NextRx Subsidiaries for $4.675 Billion 3Health News:Express Scripts Announces Definitive Agreement to Acquire WellPoint NextRx Subsidiaries for $4.675 Billion 4Health News:Express Scripts Announces Definitive Agreement to Acquire WellPoint NextRx Subsidiaries for $4.675 Billion 5Health News:Express Scripts Announces Definitive Agreement to Acquire WellPoint NextRx Subsidiaries for $4.675 Billion 6Health News:Express Scripts Announces Definitive Agreement to Acquire WellPoint NextRx Subsidiaries for $4.675 Billion 7Health News:Express Scripts Announces Definitive Agreement to Acquire WellPoint NextRx Subsidiaries for $4.675 Billion 8Health News:Racial disparities persist in the treatment of lung cancer 2Health News:New alternative to biopsy detects subtle changes in cancer cells, Stanford study shows 2Health News:New alternative to biopsy detects subtle changes in cancer cells, Stanford study shows 3Health News:Stem Cells Spur New Eggs in Ovaries of Adult Mice 2Health News:Stem Cells Spur New Eggs in Ovaries of Adult Mice 3Health News:NEWSWEEK Cover: The Mystery of Epilepsy 2Health News:NEWSWEEK Cover: The Mystery of Epilepsy 3Health News:Arthritis Hand Pain Relief: Infrared Heat Therapy Ergonomic Computer Workstation 2
Breaking Medicine Technology:Hand Surgeons Take Ethics into Their Own Hands 2Hand Surgeons Take Ethics into Their Own Hands 3Hand Surgeons Take Ethics into Their Own Hands 4Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 2Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 4National Patient Safety Foundation Supports Mandatory Flu Vaccinations for Healthcare Workers 61647 1National Patient Safety Foundation Supports Mandatory Flu Vaccinations for Healthcare Workers 61647 2National Patient Safety Foundation Supports Mandatory Flu Vaccinations for Healthcare Workers 61647 3Reportlinker Adds Biotechnology Reagents A Global Market Perspective 14905 1Reportlinker Adds Biotechnology Reagents A Global Market Perspective 14905 2Reportlinker Adds Biotechnology Reagents A Global Market Perspective 14905 3Reportlinker Adds Biotechnology Reagents A Global Market Perspective 14905 4Reportlinker Adds Biotechnology Reagents A Global Market Perspective 14905 5Reportlinker Adds Biotechnology Reagents A Global Market Perspective 14905 6Reportlinker Adds Biotechnology Reagents A Global Market Perspective 14905 7Reportlinker Adds Biotechnology Reagents A Global Market Perspective 14905 8Improving Quality Cost Effectiveness and Time Savings in Preclinical Inhalable Formulation Development 6386 1Improving Quality Cost Effectiveness and Time Savings in Preclinical Inhalable Formulation Development 6386 2